INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...

Annovis Bio (ANVS) stock slipped after the company said the FDA accepted its updated protocol for a Phase 3 trial for its ...

Nuvie Bio, a new clinical-stage biopharmaceutical company dedicated to addressing the most pressing unmet medical needs in migraine and related neurological diseases, announced completion of a ...

New Delhi: Prime Minister Narendra Modi on Thursday released the genome sequencing data of 10,000 Indian nationals.

By bridging the gap between immersive technology and user-centric design, this research paves the way for a future where VR’s ...

ASN-008 is under clinical development by Formation Bio and currently in Phase II for Notalgia Paresthetica. According to GlobalData, Phase II drugs for Notalgia Paresthetica does not have sufficient ...

ASN-008 is under clinical development by Formation Bio and currently in Phase II for Pruritus. According to GlobalData, Phase II drugs for Pruritus have a 50% phase transition success rate (PTSR) ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Macrogen a global healthcare company that specializes in precision medicine and Illumina Inc. (NASDAQ: ILMN), a global leader ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Learn more about whether Bio-Rad Laboratories, Inc. or Sotera Health Company is a better investment based on AAII's A+ ...